Cancer Discovery · 2015 · 533 citations · 44 references
Life SciencesMolecular BiologyMolecular GeneticsCancer GeneticsMolecular OncologySignal TransductionCancer ProgressionHistiocytic DisordersNeoplastic PathophysiologyNeoplastic TransformationProtein Kinase CascadesProto-oncogene ActivationKinase Domain Mutations
UNLABELLED: Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (non-LCH), respectively. The discovery of BRAF(V600E) mutations in approximately 50% of these patients provided the first molecular therapeutic target in histiocytosis. However, recurrent driving mutations in the majority of patients with BRAF(V600E)-wild-type non-LCH are unknown, and recurrent cooperating mutations in non-MAP kinase pathways are undefined for the histiocytic neoplasms. Through combined whole-exome and transcriptome sequencing, we identified recurrent kinase fusions involving BRAF, ALK, and NTRK1, as well as recurrent, activating MAP2K1 and ARAF mutations in patients with BRAF(V600E)-wild-type non-LCH. In addition to MAP kinase pathway lesions, recurrently altered genes involving diverse cellular pathways were identified. Treatment of patients with MAP2K1- and ARAF-mutated non-LCH using MEK and RAF inhibitors, respectively, resulted in clinical efficacy, demonstrating the importance of detecting and targeting diverse kinase alterations in these disorders. SIGNIFICANCE: We provide the first description of kinase fusions in systemic histiocytic neoplasms and activating ARAF and MAP2K1 mutations in non-Langerhans histiocytic neoplasms. Refractory patients with MAP2K1- and ARAF-mutant histiocytoses had clinical responses to MEK inhibition and sorafenib, respectively, highlighting the importance of comprehensive genomic analysis of these disorders.
44
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick et al. · New England Journal of Medicine · 2014 · 4.7K citations · Full text
Life Sciences, Genetics, Hematology +17
Comprehensive genomic characterization of squamous cell lung cancers
Differential analysis of gene regulation at transcript resolution with RNA-seq
Cole Trapnell, David G. Hendrickson, Martin Sauvageau et al. · Nature Biotechnology · 2012 · 3.7K citations · Full text